Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Executive appointment at Xenon

This article was originally published in Scrip

Executive Summary

Xenon Pharmaceuticals has appointed Dr Tarek Mansour as its executive vice-president of research and development. Dr Mansour recently served as vice-president, chemical sciences head over multiple research sites at Wyeth (now Pfizer) and has spent over 25 years in the industry. Xenon is a privately owned clinical genetics-based drug discovery company based in Vancouver, Canada, that has two pain medicine candidates in early-stage clinical development.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC008823

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel